111 Inc - ADR

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

111 Inc achieves operational profitability in Q1 2024 earnings call

111 Inc's Q1 2024 performance reflects a shift towards profitability, driven by operational efficiency and strategic initiatives. While facing challenges in expense optimization, the company is well-positioned to capitalize on market opportunities through listing options and expansion plans.

111 Inc reports operational profitability and strategic growth initiatives in Q2 2024

111 Inc's Q2 2024 earnings call showcased operational profitability, cost reductions, and strategic advancements in digital transformation and supply chain management. The company's focus on growth in the health care industry, expansion of patents, and plans for further logistics network development position it for continued success amidst challenges and evolving market trends.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI , Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that its release of unaudited financial results for the third quarter ended September 30, 2024, previously scheduled for Thursday, November 28, 2024, will now occur before the U.S. market opens on Wednesday, November 27, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Wednesday, November 27, 2024 (8:30 PM Beijing Time on the same day).

111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow

SHANGHAI , Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr.

111, Inc. Announces Change to Board of Directors

SHANGHAI , Oct. 22, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Wednesday, October 30, 2024 at 12:00 p.m. ET. Dr. Gang Yu, Co-Founder and Executive Chairman of 111, will discuss the Company's logistics network, including an overview of its fulfillment centers, operating models, and technological innovations enhancing procurement and last-mile delivery in addition to the network's plans for expansion.

111, Inc. to Participate in Fireside Chat with Water Tower Research on October 30, 2024

SHANGHAI , Oct. 18, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, before the U.S. market opens on Thursday, November 28, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, November 28, 2024 (8:30 PM Beijing Time on the same day).

111 to Announce Third Quarter 2024 Unaudited Financial Results on November 28, 2024 - Conference Call to Follow

SHANGHAI , Oct. 10, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that new fulfillment centers in South and Central China began operations in Guangzhou, Guangdong Province, and Wuhan, Hubei Province, respectively. These strategic expansions mark a significant step forward in enhancing its national supply chain network, increasing efficiency and speed to better meet growing market demand.

111 Inc. Expands National Supply Chain Network with New Fulfillment Centers across South and Central China

SHANGHAI , Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced it has received a notification letter dated September 26, 2024 (the "Notice") from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), indicating that for the last 30 consecutive business days, the closing bid price of the Company's American depositary shares (the "ADSs") was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1).

111, Inc. Announces Receipt of Notification from Nasdaq

Surge in demand for synthetic fibers in the medical sector for manufacturing surgical garments, wound dressings, and medical textiles. Surge in demand for synthetic fibers in the medical sector for manufacturing surgical garments, wound dressings, and medical textiles.

Synthetic Fiber Market Size is Anticipated to Reach USD 111.9 billion, Advancing at a CAGR of 4.8% by 2034: Transparency Market Research Inc.

SHANGHAI , Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today was informed by co-founders of the Company, Dr. Gang Yu and Mr.

111 Inc. Announces Its Co-founders' Strategic Share Purchase and Highlights Continued Growth and Innovation

111, Inc. (NASDAQ:YI ) Q2 2024 Earnings Conference Call August 29, 2024 7:30 AM ET Company Participants Junling Liu - Co-Founder, Chairman and CEO Luke Chen - CFO, 111's Major Subsidiary Conference Call Participants Xipeng Feng - CICC Zoe Bian - Citi Jessie Lu - HSBC Robert Sassoon - Water Tower Research Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the company are Dr. Gang Yu, Co-Founder and Executive Chairman; Mr.

111, Inc. (YI) Q2 2024 Earnings Call Transcript

Maintained Operational Profitability for the Second Consecutive Quarter Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY Held Positive Operating Cash Flow for Two Consecutive Quarters SHANGHAI , Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Net revenues were RMB3.4 billion (US$471.2 million) and gross segment profit (1) was RMB 207.6 million (US$ 28.6 million), remaining relatively flat compared to the same quarter last year.

111, Inc. Announces Second Quarter 2024 Unaudited Financial Results

SHANGHAI , Aug. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on Thursday, September 5, 2024 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q2 2024 earnings, strategic plans and goals for the second half of 2024, and the latest advancements in technology innovations and the role of AI in its supply chain platform.

111, Inc. to Participate in Fireside Chat with Water Tower Research on September 5, 2024

SHANGHAI , July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2024, before the U.S. market opens on Thursday, August 29, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 29, 2024 (7:30 PM Beijing Time on the same day).

111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow

SHANGHAI , July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced  the appointment of  Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's board of directors and audit committee.

111 Announces Appointment of New Auditor

SHANGHAI July 17, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on Thursday, July 18, 2024 at 2:00 p.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's business model, strategic goals, competitive landscape and advantages as well as its growth drivers and market opportunities.

111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024

SHANGHAI , June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced that the Company has entered into a strategic direct supply partnership (the "Partnership") with Beijing Scrianen Pharmaceutical Co., Ltd. ("Scrianen"), a comprehensive pharmaceutical enterprise that integrates research and development, production and marketing.

111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility

111, Inc. (NASDAQ:YI ) Q1 2024 Earnings Conference Call May 23, 2024 7:30 AM ET Company Participants Junling Liu - Co-Founder, Chairman and CEO Luke Chen - CFO, 111's Major Subsidiary Haihui Wang - COO Conference Call Participants Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the company are Dr. Gang Yu, Co-Founder and Executive Chairman; Mr.

111, Inc. (YI) Q1 2024 Earnings Call Transcript

Turned to Quarterly Operational Profitability for the First Time Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8% Achieved Positive Operating Cash Flow SHANGHAI , May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Net revenues were RMB3.5 billion (US$488.7 million) and Gross segment profit (1) was RMB 208.5 million (US$ 28.9 million).

111, Inc. Announces First Quarter 2024 Unaudited Financial Results

SHANGHAI , April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, before the U.S. market opens on Thursday, May 23, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day).

111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow

111, Inc. (YI) Q4 2023 Earnings Call Transcript

SHANGHAI , March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Highlights Net revenues were RMB4.1 billion (US$578.7 million), representing a decrease of 1.0% year-over-year.

111, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

SHANGHAI , March 1, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2023 ended December 31, 2023, before the U.S. market opens on Thursday, March 21, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 21, 2024 (7:30 PM Beijing Time on the same day).

111 to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results- Conference Call to Follow

SHANGHAI , Feb. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it has received a notice dated Feburary 27, 2024 on behalf of the consortium comprising Dr. Gang Yu, co-founder and co-chairman of the Company, Mr. Junling Liu, co-founder, co-chairman and chief executive officer of the Company and certain other investors (collectively, the "Consortium"), stating that the Consortium would withdraw its preliminary non-binding going private proposal dated September 9, 2022 and preliminary non-binding going private proposal dated October 29, 2022 (collectively, the "Proposals").

111 Announces Receipt of Withdrawal of Going Private Proposal

Agriforce Growing Systems Ltd

Maison Solutions Inc

Webuy Global Ltd

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 4 Defensive Stocks That Could Lead To Your Biggest Gains This Quarter - AgriFORCE Growing Systems (NASDAQ:AGRI), Maison Solutions (NASDAQ:MSS)

111, Inc. (NASDAQ:YI ) Q3 2023 Results Conference Call November 30, 2023 7:30 AM ET Company Participants Gang Yu - Co-Founder and Executive Chairman Junling Liu - Co-Founder, Chairman and CEO Luke Chen - CFO of 111's Major Subsidiary Haihui Wang - COO Conference Call Participants Xipeng Feng - CIBC Tom Craig - Cornerstone Investment Ethan Ling - Iron Harbor Capital Operator Hello, everyone, and thank you for joining 111's Conference Call today. On the call today from the company are Dr. Gang Yu, Co-Founder and Executive Chairman; Mr.

111, Inc. (YI) Q3 2023 Earnings Call Transcript

SHANGHAI , Nov. 30, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights Net revenues were RMB3.7 billion (US$502.4 million), representing an increase of 9.5% year-over-year.

News for 111 Inc - ADR Stock (YI)